Literature DB >> 6433043

Verapamil enhancement of chemotherapeutic efficacy in human bladder cancer cells.

W G Simpson, M T Tseng, K C Anderson, J I Harty.   

Abstract

The calcium influx blocker verapamil has been used to overcome drug resistance in several tumor systems. The possible in vitro enhancement of drug efficacy was assessed in bladder cancer cell line T24. Combination of thiotepa and doxorubicin hydrochloride with verapamil significantly reduced the survival and growth of T24 cells after as little as 1 hour of drug exposure. An increase in doxorubicin hydrochloride-induced inhibition of [3H]thymidine uptake resulted when verapamil was administered. However, this trend was not demonstrated when combined with thiotepa. It appears that verapamil enhances thiotepa-induced cytotoxicity while it potentiates the antimitotic nature of doxorubicin hydrochloride. The data presented is consistent with the postulate that verapamil alters active efflux of drug from malignant cells and suggests that verapamil has a role in the clinical management of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6433043     DOI: 10.1016/s0022-5347(17)49749-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  Verapamil enhanced in vitro chemosensitivity of a murine bladder carcinoma, FCB.

Authors:  R J Ballou; W G Simpson; J I Harty; M T Tseng
Journal:  Urol Res       Date:  1986

2.  Enhancement of the cytogenetic efficacy of the antitumor agent bleomycin by the calcium and calmodulin antagonist fendiline.

Authors:  W Scheid; H Traut
Journal:  Experientia       Date:  1988-03-15

3.  Establishment and characterization of a multidrug-resistant human bladder carcinoma cell line RT112/D21.

Authors:  O Seemann; M Muscheck; M Siegsmund; H Pilch; C T Nebe; J Rassweiler; P Alken
Journal:  Urol Res       Date:  1995

4.  Ultrastructural evaluation of murine bladder epithelium exposed to verapamil.

Authors:  M T Tseng; W Simpson; J I Harty
Journal:  Urol Res       Date:  1985

5.  Intravesical instillation chemotherapy of adriamycin with or without verapamil for the treatment of superficial bladder cancer: the final results of a collaborative randomized trial.

Authors:  T Tsushima; H Ohmori; Y Ohi; T Shirahama; M Kawahara; Y Matsumura; Y Ohashi
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Prophylactic intravesical chemotherapy with adriamycin plus verapamil for primary superficial bladder cancer: preliminary results. The Kyushu University Urological Oncology Group.

Authors:  S Naito; T Ueda; S Kotoh; A Iguchi; K Sagiyama; Y Hiratsuka; Y Osada; A Ariyoshi; T Omoto; J Kumazawa
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Measurement of BBN-induced alterations in rat urothelium by electron microscopic X-ray microanalysis.

Authors:  R Sikora; D Rohde; W G Burchard; A Zumbrägel; G Jakse
Journal:  Urol Res       Date:  1994

Review 8.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

9.  Systemic influence of intravesical chemotherapy with verapamil.

Authors:  W G Simpson; M T Tseng; J I Harty
Journal:  Urol Res       Date:  1985

10.  Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.

Authors:  B A Robinson; R D Clutterbuck; J L Millar; T J McElwain
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.